Exelixis: A Quietly Thriving Biotech with Room for Growth in 2026

Exelixis is a biotech company that has delivered strong financial results and solid returns over the past five years. Its cancer drug, Cabometyx, has been approved across a range of indications and has been the top-prescribed cancer drug in renal cell carcinoma. The company is preparing for the eventuality of Cabometyx facing generics with its newer drug, zanzalintinib, which completed a phase 3 study as a combination treatment for metastatic colorectal cancer.